|
MechanismProto-oncogene protein c-fli-1 inhibitors |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
TK216在中国复发或难治性尤文肉瘤受试者中的有效性和安全性的II期临床试验
[Translation] A Phase II clinical trial of the efficacy and safety of TK216 in Chinese subjects with relapsed or refractory Ewing sarcoma
初步探索TK216联合长春新碱治疗复发或难治性尤文肉瘤(ES)受试者的有效性。
[Translation] To preliminarily explore the effectiveness of TK216 combined with vincristine in the treatment of subjects with relapsed or refractory Ewing sarcoma (ES).
100 Clinical Results associated with Shanghai Pharmaceutical Usa, Inc.
0 Patents (Medical) associated with Shanghai Pharmaceutical Usa, Inc.
100 Deals associated with Shanghai Pharmaceutical Usa, Inc.
100 Translational Medicine associated with Shanghai Pharmaceutical Usa, Inc.